Table 2. Baseline demographics and clinical risk factors by baseline diastolic blood pressure.
DBP: diastolic blood pressure; MI: myocardial infarction; ECG: electrocardiogram
| BASELINE DBP (MM HG) | ||||||
|---|---|---|---|---|---|---|
| <60 (n=226) | 60–69 (n=2,015) | 70–79 (n=8,109) | 80–89 (n=13,841) | 90–99 (n=8,146) | ≥100 (n=1,020) | |
| AGE, YEARS, MEAN (SD) | 72.1 (7.8) | 72.1 (7.8) | 68.9 (7.7) | 67.3 (7.5) | 65.4 (7.3) | 63.7 (6.9) |
| MALE SEX | 127 (56.2) | 1,038 (51.5) | 4,195 (51.7) | 7,370 (53.3) | 4,418 (54.2) | 571 (56.0) |
| RACE | ||||||
| WHITE | 147 (65.0) | 1,291 (64.1) | 5,081 (62.7) | 8,351 (60.3) | 4,552 (55.9) | 502 (49.2) |
| BLACK | 70 (30.1) | 605 (30.0) | 2,615 (32.3) | 4,839 (35.0) | 3,183 (39.1) | 478 (46.9) |
| OTHER | 9 (4.0) | 119 (5.9) | 413 (5.1) | 651 (4.7) | 411 (5.0) | 40 (3.9) |
| BMI, KG/M2, MEAN (SD) | 28.8 (5.5) | 28.8 (5.5) | 29.1 (5.7) | 29.7 (5.9) | 29.9 (6.0) | 30.2 (6.0) |
| SMOKER | ||||||
| NEVER | 58 (25.6) | 721 (35.8) | 3,001 (37.0) | 5,328 (38.5) | 3,114 (38.2) | 383 (37.6) |
| CURRENT | 44 (19.5) | 371 (18.4) | 1,589 (19,6) | 2,917 (21.1) | 2,079 (25.5) | 303 (29.7) |
| PAST | 124 (54.9) | 923 (45.8) | 3,519 (43.4) | 5,595 (40.4) | 2,953 (36.3) | 334 (32.8) |
| HISTORY OF: | ||||||
| CORONARY HEART DISEASE | 70 (31.8) | 659 (33.3) | 2,317 (29.0) | 3,449 (25.2) | 1,698 (21.0) | 210 (20.8) |
| MI OR STROKE | 48 (21.2) | 560 (27.8) | 2,035 (25.1) | 3,270 (23.6) | 1,640 (20.1) | 187 (18.3) |
| CORONARY REVASCULARIZATION | 54 (23.9) | 405 (20.1) | 1,347 (16.6) | 1,752 (12.7) | 677 (8.3) | 75 (7.4) |
| OTHER ATHEROSCLEROSIS | 81 (35.8) | 601 (29.8) | 2,089 (25.8) | 3,194 (23.1) | 1,741 (21.4) | 195 (19.1) |
| MAJOR ECG CHANGES | 23 (10.5) | 196 (9.9) | 799 (10.0) | 1,400 (10.2) | 867 (10.7) | 135 (13.4) |
| TYPE 2 DIABETES MELLITUS | 98 (43.4) | 911 (45.2) | 3,257 (40.2) | 5,080 (36.7) | 8,146 (30.3) | 250 (24.5) |
| HDL<35 MG/DL | 25 (11.1) | 223 (11.1) | 1,007 (12.4) | 1,664 (12.0) | 880 (10.8) | 78 (7.7) |
| ASPIRIN USE | 104 (46.0) | 935 (46.4) | 3,259 (40.2) | 4,961 (35.8) | 2,463 (30.2) | 230 (22.6) |
| ON ANTIHYPERTENSIVE MEDICATION AT BASELINE | 220 (97.3) | 1,937 (96.1) | 7,658 (94.4) | 12,720 (91.9) | 6,588 (80.9) | 624 (61.2) |
| SBP, MEAN (SD) | 137.9 (13.7) | 136.9 (12.1) | 137.7 (11.4) | 139.2 (10.8) | 141.7 (10.9) | 147.0 (12.6) |
| DBP, MEAN (SD) | 64.4 (6.7) | 69.6 (5.6) | 75.2 (5.3) | 80.3 (5.3) | 85.0 (6.0) | 90.2 (7.1) |
| PP, MEAN (SD) | 73.5 (15.1) | 67.4 (12.4) | 62.5 (11.1) | 58.9 (10.0) | 56.7 (9.1) | 56.7 (9.2) |
| RANDOMIZATION GROUP | ||||||
| CHLORTHALIDONE | 106 (46.9) | 899 (44.6) | 3,721 (45.9) | 6,366 (46.0) | 3,706 (45.5) | 457 (44.8) |
| AMLODIPINE | 65 (28.8) | 585 (29.0) | 2,189 (27.0) | 3,720 (26.9) | 2,208 (27.1) | 281 (27.6) |
| LISINOPRIL | 55 (24.3) | 531 (26.4) | 2,199 (27.1) | 3,755 (27.1) | 2,232 (27.4) | 282 (27.6) |